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The glucocorticoid receptor (GR) and the tumor supressor p53 mediate different stress responses. We have
studied the mechanism of their mutual inhibition in normal endothelial cells (HUVEC) in response to
hypoxia, a physiological stress, and mitomycin C, which damages DNA. Dexamethasone (Dex) stimulates the
degradation of endogenous GR and p53 by the proteasome pathway in HUVEC under hypoxia and mitomycin
C treatments, and also in hepatoma cells (HepG2) under normoxia. Dex inhibits the functions of p53
(apoptosis, Bax, and p21WAF1/CIP1 expression) and GR (PEPCK and G-6-Pase expression). Endogenous p53 and
GR form a ligand-dependent trimeric complex with Hdm2 in the cytoplasm. Disruption of the p53–HDM2
interaction prevents Dex-induced ubiquitylation of GR and p53. The ubiquitylation of GR requires p53, the
interaction of p53 with Hdm2, and E3 ligase activity of Hdm2. These results provide a mechanistic basis for
GR and p53 acting as opposing forces in the decision between cell death and survival.
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The development of most tumors is associated with loss
of function of the tumor suppressor p53. Different physi-
ological stress, including DNA damage and hypoxia, ac-
tivate p53. p53 is a transcription factor that regulates
genes involved in growth arrest and apoptosis. p53 is
down-regulated by its target gene product Mdm2 (human
homolog Hdm2). Mdm2 forms an autoregulatory loop
with p53 by binding to its N-terminal domain, inhibiting
its transcriptional activity and increasing its degradation
by the ubiquitin proteasome pathway (for reviews, see
Jimenez et al. 1999; Lakin and Jackson 1999; Sionov and
Haupt 1999). Mdm2 is a RING finger-dependent ubiqui-
tin protein ligase for p53 and itself (Argentini et al. 2000;
Fang et al. 2000; Honda and Yasuda 2000). Mdm2 also
inhibits p53 by nuclear export through a mechanism in-
volving either the nuclear export signal (NES) of Mdm2
(Tao and Levine 1999) or the RING finger of Mdm2 and
the NES of p53 (Boyd et al. 2000; Geyer et al. 2000). The
NES of p53 is masked in the transcriptionally active het-
erodimer, but is exposed in the monomeric form of p53
(Stommel et al. 1999). MdmX, a Mdm2 homolog that
lacks a NES, stabilizes p53 by retention in the nucleus
(Jackson and Berberich 2000; Stad et al. 2000). Nuclear
p53 levels can also be maintained by ARF, which blocks
nucleo-cytoplasmic shuttling of Mdm2 (Sherr and Weber
2000). Most studies of p53 involve DNA damaging drugs
and radiation. Much less is known about the physiologi-
cal stress, hypoxia. Under hypoxic conditions, p53 is sta-
bilized by mitochondria through a redox-dependent
mechanism (Chandel et al. 2000) and by HIF-1 (An et al.
1998), whereas p53 induces degradation of HIF-1 (Ravi
et al. 2000). The response to hypoxia in vivo also in-
volves the glucocorticoid receptor (GR) (Bauer et al.
1999).
GR is a member of the steroid receptor superfamily
that mediates physiological processes controlled by glu-
cocorticoids. In the unbound state GR is located in the
cytoplasm bound to chaperones. Upon ligand binding the
chaperones dissociate, exposing the NLS that enables
GR to enter the nucleus and regulate transcription
(Cheung and Smith 2000). GR activates transcription by
binding to glucocorticoid response elements (GREs), and
represses by binding to negative and composite elements
(Kellendonk et al. 1999). GR mediates stress responses,
and animals that overexpress GR are more resistant to
stress and endotoxic shock (Reichardt et al. 2000).
Recently, evidence has been growing for cross talk be-
tween the p53 and GR-mediated responses to stress. p53
physically interacts with and represses the activities of
GR (Sengupta et al. 2000b). Modulation of glucocorti-
coid-induced apoptosis has been linked to p53 gene dos-
age in mice (Mori et al. 1999). Glucocorticoids prevent
p53-induced apoptosis in immortalized human granulo-
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sa cells (Sasson et al. 2001). p53 and GR regulate in op-
posite manners the type II hexokinase gene, whose over-
expression is associated with increased glucose catabo-
lism in cancer cells (Mathupala et al. 1997). Hypoxia
leads to p53 activation and decreased glucose metabo-
lism (Riva et al. 1998). Because little is known about the
functional interactions between the signalling pathways
mediated by p53 and GR under physiological conditions,
we have investigated how p53 and GR regulate each
other under hypoxia. We show that they mutually in-
hibit each other’s activity by cytoplasmic sequestration
in a ligand-dependent manner, which leads to increased
degradation through recruitment of the E3 ubiquitin li-
gase Hdm2 and the proteasome pathway.
Results
Dexamethasone enhances the interaction of GR
with the core domain and NLS of p53
We have reported previously that p53 and GR interact in
vivo (Sengupta et al. 2000b). We used in vitro GST pull-
down assays to determine which region of p53 interacts
with GR (Fig. 1A, left). The GST fusion proteins were
produced in Escherichia coli, purified on Glutathione
Sepharose beads, and equivalent amounts of protein
(judged by Coomassie blue staining, Fig. 1B), were used.
Full-length p53 interacted with GR weakly but specifi-
cally in the absence of ligand (Fig. 1A,C, lanes 3 and 6).
This interaction was enhanced by the agonists Dexa-
methasone (Dex) or Cortisol (Cort), and inhibited by the
antagonist RU486 (Fig. 1C, lanes 2–6). These results
show that the binding of GR to p53 is enhanced by ago-
nists in vitro. In the presence of ligand, GR interacted
with both the core domain [GST–p53(76–304)] and the
NLS [GST–p53(305–320)] of p53, and more strongly with
a mutant containing both regions [GST–p53(76–320)].
No interaction was detected between GR and either the
N-terminal [GST–p53(1–75)] or C-terminal [GST–
p53(321–362) and GST–p53(363–393)] domains. The mu-
tant containing both interaction domains [GST–p53(76–
320)] interacted more strongly than the full-length pro-
tein, raising the possibility that it lacks sequences that
inhibit the interaction with GR. The interactions be-
tween GR and deletion mutants containing the NLS
[GST–p53(76–320) and GST–p53(305–320)] were inhib-
ited by a peptide containing the NLS (amino acids 305–
320, Pep, Fig. 1C, lanes 7–11), confirming that the GR–
p53 NLS interaction is specific.
GR interacts with the central region of p53, suggesting
that it should inhibit the Chimeric Tumor Supressor,
CTS1, that harbors this domain of p53 linked to heter-
ologous activation and dimerization domains (Conseiller
et al. 1998) (Fig. 1D, top left). The transcriptional activity
of CTS1 was measured in p53 null HSC-2 cells with the
p53CON reporter (Fig. 1D, top right). Vehicle alone
(ethanol), Dex, and RU486 did not affect the basal activ-
ity of the reporter (Fig. 1D, lanes 1–3). Increasing
amounts of CTS1 stimulated reporter activity in a dose-
dependent manner (Fig. 1D, lanes 4–6). CTS1 was inhib-
ited around threefold by endogenous GR activated with
Dex, but was not affected by RU486 (Fig. 1D, lanes 7–12).
With a constant level of CTS1, exogenous GR inhibited
CTS1 activity to a small extent (Fig. 1D, lanes 13–16),
and the addition of Dex increased this inhibition (Fig.
1D, lanes 17–19). In contrast, GR, in the presence of
RU486, had little effect (Fig. 1D, lanes 20–22). Similar
results were obtained in Saos-2 cells (data not shown).
These results indicate that the region of p53 that inter-
acts with GR in vitro is sufficient for efficient repression
by GR in vivo.
Dex decreases p53 and GR levels and inhibits
expression of their target genes in HepG2 cells
Cytoplasmic p53 in neuroblastoma cells is released from
its complex with GR and translocates to the nucleus
following treatment with GR antagonists (Sengupta et
al. 2000b). We investigated whether cytoplasmic p53 in
other tumor cell types, such as HepG2 (hepatoma)
and SA1 (osteosarcoma) (Wasylyk et al. 1999; Lu et al.
2000), behaved similarly. Under normal growth con-
ditions, Dex increased the amount of p53 and GR in
the cytoplasm of both cell lines, although some p53
always remained nuclear. In contrast, RU486 signifi-
cantly increased the amount of nuclear p53 (data not
shown). Interestingly, in HepG2 cells, Dex caused a
drastic decrease in the protein levels of both p53 and GR
(Fig. 2A, lanes 1,2). This effect was blocked by the pro-
teasome inhibitor LLnL (Fig. 2A, lanes 3,4), suggesting
that the decrease is due to enhanced degradation. We
investigated whether Dex can inhibit the expression of
genes downstream from both p53 (Bax, Hdm2, and
p21WAF1/CIP1) and GR (phospho enol pyruvate carboxy
kinase, PEPCK; Imai et al. 1990). Dex decreased Bax and
p21WAF1/CIP1 protein levels (Fig. 2B) and promoter activ-
ity (reporter assays; data not shown). Dex did not affect
either the level of Hdm2 protein (Fig. 2B), or the activity
of the promoter (reporter assay, data not shown), show-
ing that Hdm2 expression is less sensitive than Bax or
p21WAF1/CIP1 to changes in p53 levels. Dex decreased
PEPCK protein levels (Fig. 2B). These results show that
Dex down-regulates both p53 and GR protein levels and
the expression of their downstream targets in HepG2
cells.
Dex activation of endogenous GR inhibits p53
induction by hypoxia in normal endothelial
cells (HUVEC)
HepG2 is a tumor cell line with undefined genetic alter-
ations. Hence, we investigated in normal human cells
(HUVEC) the response to hypoxia, a natural inducer of
p53. Normally growing HUVEC express very little or no
p53 protein (Fig. 3A, lane 1). p53 was strongly induced
after 12 h of hypoxia, and increased further after 18 h
(Fig. 3A, lanes 3,5). Dex inhibited the induction of p53 up
to 36 h (Fig. 3A, lanes 2–5; data not shown). The protea-
some inhibitor, LLnL, decreased Dex-dependent inhibi-
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tion of p53 induction, without substantially affecting the
level of p53 in the absence of ligand (Fig. 3A, lanes 6–9).
p53 RNA levels detected by Northern blotting were not
affected by Dex (Fig. 3B), showing that the inhibitory
effect of Dex on p53 is not due to changes in transcrip-
tion or RNA stability. In conclusion, Dex decreases p53
stability by enhanced proteasomal degradation.
The products of the p53 downstream genes Bax and
Figure 1. The core domain and the NLS of p53 interact with GR and attenuate transactivation by GR. (A) Schemes. The GST
constructs are shown on the left, and the extent of their interaction with full-length GR is summarized on the right. AD1, activation
domain 1; AD2, activation domain 2; DBD, DNA binding domain; NLS, nuclear localization signal; TD, tetramerization domain; +,
detectable interaction; −, undetectable interaction. The numbers indicate the amino acids of human p53. (B) Coomassie stained gel.
The proteins of interest are indicated by arrows. (Lane 1) molecular weight marker (M); (lane 2) GST; (lane 3) GST–p53; (lane 4)
GST–p53(76–320); (lane 5) GST–p53(76–304); (lane 6) GST–p53(305–320). (C) Equal amounts of in vitro translated GR (lanes 2–12) were
incubated with wild-type or mutant p53 fusion proteins, vehicle (ethanol), 10−7 M ligands or 50 µM peptide (Pep), as indicated. (Lane
1) Input, 5%; (lane 2) GST–p53 + Dex; (lane 3) GST–p53; (lane 4) GST–p53 + RU486; (lane 5) GST–p53 + Cortisol; (lane 6) GST; (lane
7) GST–p53(76–320) + Dex; (lane 8) GST–p53(76–304) + Dex; (lane 9) GST–p53(305–320) + Dex; (lane 10) GST–p53(305–
320) + Pep + Dex; (lane 11) GST–p53(76–320) + Pep + Dex; (lane 12) GST–p53(305–320). (D) p53 null HSC-2 cells were transfected with
CTS1 (top left), and p53 activity was measured with the p53 CON reporter (top right, all lanes). Vehicle (ethanol, −), 10−7 M Dex or
10−7 M RU486 were added as indicated. (Lane 1) No ligand; (lane 2) +Dex; (lane 3) +RU486; (lanes 4–6) CTS1 (125, 250, 500 ng/mL);
(lanes 7–9) CTS1 (125, 250, 500 ng/mL) +Dex; (lanes 10–12) CTS1 (125, 250, 500 ng/mL) + RU486; (lane 13) CTS1 (500 ng/mL); (lanes
14–16) CTS1 (500 ng/mL) + GR (250, 500, 1250 ng/mL); (lanes 17–19) CTS1 (500 ng/mL) + GR (250, 500, 1250 ng/mL) +Dex; (lanes
20–22) p53 (500 ng/mL) + GR (250, 500, 1250 ng/mL) + RU486. Luciferase activity was measured 24 h post-transfection and corrected
for transfection efficiency. The values shown are from four independent experiments. VP16, HSV1 VP16 transcription activation
domain; DBD, DNA binding domain; NLS, nuclear localization signal; LZ, leucine zipper; p53 RE, p53 responsive element; TATA,
minimal promoter element.
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p21WAF1/CIP1 were induced by hypoxia (Fig. 3C, lanes
1,3,5,7). p21WAF1/CIP1 has also been shown to be induced
by hypoxia in normal fibroblasts but not in several trans-
formed cell lines (Ashcroft et al. 2000; Koumenis et al.
2001). Bax and p21WAF1/CIP1 induction was inhibited by
Dex (Fig. 3C, lanes 2,4,6). Under normoxia, in which p53
levels are very low, Dex had no effect, indicating that
Dex inhibition of p53 downstream genes is p53 depen-
dent (Fig. 3C, lanes 8–11). HIF-1 stabilizes p53 in re-
sponse to hypoxia (An et al. 1998), which raised the pos-
sibility that it, too, is affected by Dex. However, HIF-1
induction by hypoxia in HUVEC was not significantly
affected by Dex (Fig. 3D). The apparently weak induction
of HIF-1 is consistent with the low level of HIF-1 RNA
in endothelial cells (Tian et al. 1997). Dex did, however,
inhibit Hdm2 induction until 12 h under hypoxia (Fig.
3E, lanes 2,3). In the presence of LLnL the difference in
the level of induction was no longer observed, indicating
that the difference is due to Dex-induced proteasomal
degradation (Fig. 3E, lanes 6,7). After 18 and up to 36 h
the levels of Hdm2 were similar, irrespective of the pres-
ence of Dex and LLnL (Fig. 3E, lanes 4,5,8,9; data not
shown). Hypoxia induces apoptosis of HUVEC in a p53-
dependent manner (Stempien-Otero et al. 1999). We,
therefore, investigated whether Dex affected apoptosis
by following PARP cleavage and DNA fragmentation.
PARP cleavage, an early marker of apoptosis, was de-
tected at 18 h and increased up to 36 h (Fig. 3F, lanes
1–5). Dex inhibited PARP cleavage up to 36 h under hyp-
oxia (Fig. 3F, lanes 6–8). Similar results were obtained
using DNA fragmentation (data not shown). These re-
sults show that the activation of endogenous GR with
Dex in HUVEC, as well as HepG2, dramatically de-
creases p53 downstream functions.
Dex-dependent GR degradation by a proteasome
pathway and inhibition of its target genes
under hypoxia
Hypoxia has been shown to affect GR functions and lev-
els of expression in several systems (Jenq et al. 1996;
Bauer et al. 1999). Therefore, we investigated whether
hypoxia affects GR in HUVEC. Hypoxia alone caused a
reproducible increase in GR protein levels (Fig. 4A, lanes
1,3,7), which was down-regulated by Dex (Fig. 4A, lanes
2,3,6,7). This down-regulation was blocked by the pro-
teasome inhibitor LLnL (Fig. 4A, lanes 4,5,8,9). As Dex
had no effect on GR at the RNA level under hypoxia
(data not shown), we conclude that GR is decreased at
the protein level by a proteasome-mediated process in
response to Dex under hypoxic conditions, similar to p53
(see above).
We next investigated whether hypoxia affects Dex in-
duction of the GR downstream genes PEPCK (Imai et al.
1990) and Glucose-6-Phosphatase (G-6-Pase) (Argaud et
al. 1996). Whereas Dex induced RNA expression from
both of these genes under normoxia (Fig. 4B, lanes 1,2),
hypoxia blocked this induction (Fig. 4B, lanes 3,4). Simi-
larly, hypoxia blocked PEPCK protein induction (data
not shown). These results concur with studies in rat he-
patocytes, where in vivo hypoxic exposure inhibits glu-
coneogenesis at the PEPCK level due to decreased
PEPCK gene transcription (Pison et al. 1995).
p53, GR, and Hdm2 colocalize in the cytoplasm
in the presence of ligand
Our experiments show that p53 and GR are degraded by
proteasomes in HepG2 under normal growth conditions
and in HUVEC under hypoxia. Because subcellular lo-
calization affects p53 degradation, we studied the local-
ization of p53 and GR in HUVEC cells (Fig. 5). As ex-
pected, under normal conditions p53 was not detectable
(Fig. 5A), because of its very low level of expression (see
above). GR was located in the cytoplasm in the absence
of ligand, but accumulated in the nucleus in the presence
of Dex. Under hypoxic conditions, in the absence of Dex,
p53 was detectable and was localized to both the nucleus
and the cytoplasm in the majority of cells (65%), and
exclusively in the nucleus in about 25%, whereas GR
remained in the cytoplasm (Fig. 5B). In the presence of
Dex, p53 was completely cytoplasmic in around 60% of
the cells, and was colocalized extensively with GR. The
immunofluorecence of both GR and p53 was, however,
considerably lower, as expected from their degradation
(see above). To confirm these data, LLnL was used to
stabilize the proteins and increase the signal. Typical
cells are shown in Figure 5C–E, and the quantification in
Figure 5F. The presence of LLnL did not change the re-
sults overall, but the effects were more pronounced. p53
was detected in the nucleus in almost 90% of the cells in
the absence of Dex. However, in the presence of ligand,
p53 and GR colocalized extensively in the cytoplasm
(Fig. 5C).
Hdm2 is involved in p53 degradation and export from
Figure 2. p53 and GR undergo ligand and proteasome-depen-
dent degradation in HepG2 cells. (A) HepG2 cells were grown
for 12 h with vehicle (ethanol), 10−7 M Dex, and 50 µM LLnL, as
indicated. Proteins (50 µg) were analyzed by Western blotting
with antibodies to: (a) GR (E-20 and P-20); (b) p53 (DO-1); (c)
TBP (3G3). (Lane 1) +Dex; (lane 2) (−, vehicle); (lane 3)
+Dex + LLnL; (lane 4) (−, vehicle) + LLnL. (B) Lysates from cells
incubated in the absence of LLnL were Western blotted with
antibodies to: (a) Bax (N-20); (b) p21WAF1/CIP1 (1WA-IC581); (c)
Hdm2 (2A10); (d) PEPCK; (e) TBP (3G3). (Lane 1) +Dex; (lane 2)
(−, vehicle).
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Figure 3. Dex inhibits induction by hypoxia of p53 protein levels, expression of p53 target genes, and apoptosis. (A) HUVEC cells were
grown for different times with, as indicated, vehicle (ethanol), 10−7 M Dex, and 50 µM LLnL, under normoxic (−, lane 1) or hypoxic
(lanes 2–9) conditions. Lysates (50 µg) were analyzed by SDS-PAGE andWestern blotting with antibodies against (a) p53 (DO-1); (b) TBP
(3G3). (Lanes 1,3,5) (−, vehicle); (lanes 2,4) +Dex; (lanes 6,8) +Dex + LLnL; (lanes 7,9) (−, vehicle) + LLnL. (B) Total RNA was extracted
from HUVEC cells grown with vehicle (ethanol) or 10−7 M Dex and hypoxia for 18 h. The RNAs (40 µg) were run on formaldehyde–
agarose gels and northerns were hybridized with probes against (a) p53, (b) -actin. (Lane 1) +Dex; (lane 2) (−, vehicle). (C) HUVEC were
grown under normoxia (lanes 1,8–11) or hypoxia (lanes 2–7) with vehicle (ethanol) or Dex. Lysates (50 µg, lanes 1–7; 200 µg, lanes 8–11)
were Western blotted with antibodies against (a,d) p21WAF1/CIP1 (1WA-IC581); (b,e) Bax (N-20); (c,f) TBP (3G3). (Lanes 1, 3,5,7,9,11) (−,
vehicle); (lanes 2,4,6,8,10) +Dex. (D) HUVEC were grown under normoxia (lane 1) or hypoxia (lanes 2–5) with vehicle (ethanol) or Dex.
Lysates (50 µg) were Western blotted with antibodies against HIF-1 (C-19). (Lanes 1,3,5) (−, vehicle); (lanes 2,4) +Dex. CR, cross-
reacting band. (E) HUVEC were grown under normoxia (lane 1) or hypoxia (lanes 2–9) with vehicle (ethanol), Dex, and 50 µM LLnL,
as indicated. Lysates (50 µg) wereWestern blotted with antibodies to (a) Hdm2 (2A10), (b) TBP (3G3). (Lanes 1,3,5,7,9) (−, vehicle); (lanes
2,4,6,8) +Dex. (F) HUVEC were grown under normoxia (lane 1) or hypoxia (lanes 2–8). Lysates (50 µg) were Western blotted with
polyclonal antibodies against PARP. (Lanes 1–5) (−, vehicle); (lanes 6–8) +Dex. FL, full length. The cleavage products were scanned and
the values are the amount of the cleaved product relative to lane 5.
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the nucleus, raising the possibility that it may also be
implicated in GR turnover and localization. As expected,
Hdm2 was found to be predominantly nuclear under
hypoxia and in the absence of ligand. Interestingly,
Hdm2 was cytoplasmic and extensively colocalized with
GR in the presence of ligand (Fig. 5D). Similarly, Hdm2
was found to colocalize with p53 in the nucleus in the
absence of ligand and in the cytoplasm in the presence of
Dex (Fig. 5E).
The ligand-dependent trimeric complex between p53,
GR, and Hdm2 enhances proteasomal degradation
The colocalization of p53, GR, and Hdm2 in the cyto-
plasm led us to investigate whether they form a trimeric
complex. Coimmunoprecipitation assays were per-
formed on extracts from HUVEC that had been exposed
to hypoxia in the presence of LLnL and in the presence or
absence of Dex. Equivalent amounts of p53 were immu-
noprecipitated with the anti-p53 antibody, irrespective
of the presence of ligand, as expected from the inhibition
of p53 degradation by LLnL (Fig. 6A, c). The p53-antibody
immunoprecipitate contained both GR and Hdm2 in sig-
nificantly higher amounts in the presence of Dex than in
its absence (Fig. 6A, a,b, lanes 3,4). In the reciprocal ex-
periment, the GR-antibody immunoprecipitates con-
tained equivalent amounts of GR irrespective of Dex
treatment (Fig. 6A, f). They also contained both p53 and
Hdm2 in significantly higher amounts in the presence of
Dex (Fig. 6A, d,e, lanes 7,8). Similar results were ob-
tained in HepG2 cells, where p53, GR and Hdm2 formed
a trimeric complex more efficiently following Dex treat-
ment of the cells (Fig. 6B).
GR has been postulated to be degraded by the ubiqui-
tin–proteasome pathway (Whitesell and Cook 1996; Seg-
nitz and Gehring 1997), but there was no direct evidence.
Our results do indicate, however, that during cross talk
between the GR and p53 pathways, GR is degraded
concurrently with p53 by a pathway involving the E3
ubiquitin ligase activity of MDM2. To test this hypoth-
esis HUVEC cells were transfected with HA-tagged ubiq-
uitin (HA-Ub) in the presence or absence of IP3, a small
peptide that specifically disrupts the p53–Hdm2 interac-
tion (Wasylyk et al. 1999). Twenty-four hours post-trans-
fection, the cells were placed under hypoxic conditions
in the presence of the proteasome inhibitor, LLnL. West-
ern blotting of HA-immunoprecipitates with GR anti-
bodies showed that GR was poly-ubiquitinated, but only
when the cells were incubated in the presence of Dex
(Fig. 6C, a, lanes 1,2). IP3 expression inhibited GR poly-
ubiquitylation, showing that it requires the p53–Hdm2
interaction (Fig. 6C, a, lanes 1,3). The poly-ubiquitinated
forms are specific, because they were not detected when
HA-Ub was not transfected (Fig. 6C, a, lanes 5,6). Inter-
estingly, polyubiquitylation of p53 is also enhanced in
the presence of Dex (Fig. 6C, b, lanes 1,2). Polyubiqui-
tylation of p53 was inhibited by the expression of IP3,
as expected from the disruption of the p53–Hdm2 in-
teraction (Fig. 6C, b, lanes 1,3). These results show
that Dex stimulates GR and p53 polyubiquitylation
through a pathway involving Hdm2 and its interaction
with p53.
The E3 ligase activity of Hdm2 is responsible
for ligand-dependent degradation of GR
To study GR degradation in transfection assays, in
which exogenous proteins are expressed in cells, we used
HCT116 isogenic cell lines in which p53 is either wild
type or disrupted by homologous recombination (Bunz et
al. 1998). The isogenic cell lines were transfected with
recombinants that express HA-Ub and IP3. Posttransfec-
tion, the cells were subjected to hypoxia in the presence
of Dex and LLnL. HA-antibody immunoprecipitates con-
tained lower mobility HA-tagged polyubiquitylated
forms of GR (Fig. 6D, a, lane 1). IP3 expression inhibited
ubiquitylation of GR (Fig. 6D, a, lane 2). Ubiquitylated
GR was not detected in cells lacking p53, whether or not
IP3 was expressed (Fig. 6D, a, lanes 3,4). These results
indicate that GR ubiquitylation requires p53 and its in-
teraction with Hdm2. In cells that were not treated with
LLnL, IP3 expression increased the levels of both GR and
p53 (Fig. 6D, a, lanes 5,6), as expected from decreased
degradation of both proteins by a common mechanism
Figure 4. Dex enhances proteasome-mediated degradation of GR and prevents up-regulation of its target genes under hypoxia. (A)
HUVEC were grown with vehicle (ethanol), 10−7 M Dex, and 50 µM LLnL, as indicated under normal (lane 1) or hypoxic (lanes 2–9)
conditions. Lysates (50 µg) were Western blotted with antibodies to (a) GR (E-20 and P-20); (b) TBP (3G3). (Lanes 1,3,5) (−, vehicle);
(lanes 2,4) +Dex; (lanes 6,8) +Dex + LLnL; (lanes 7,9) (−, vehicle) + LLnL. (B) Total RNA from HUVEC grown in normoxia (lanes 1,2)
or hypoxia (lanes 3,4) for 18 h with vehicle (ethanol) or 10−7 MDex. Northerns were hybridized with probes for (a) PEPCK; (b) G-6-Pase;
(c) -actin. (Lanes 1,3) +Dex; (lanes 2,4) (−, vehicle).
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involving Hdm2. Irrespective of the presence or absence
of IP3, GR levels were higher in the isogenic p53−/− cells
(Fig. 6D, a, lanes 7,8), as expected from the lack of p53
that is required to recruit Hdm2.
To confirm that p53–Hdm2 interactions are required
for GR degradation, we used p53(22,23), which cannot
interact with Hdm2 (Lin et al. 1994). Expression of wild-
type p53, Hdm2, and exogenous GR in HCT116 p53−/−
cells in the presence of Dex resulted in a significant
decrease in GR levels (Fig. 6E, lanes 1–4). In contrast,
the GR levels remained unchanged when the p53(22,23)
mutant was expressed (Fig. 6E, lane 5). Interestingly,
similar to GR, the levels of p53 and Hdm2 were also
higher with p53(22,23) compared to p53 wild type (Fig.
6E, lanes 5,6). These results suggest that Dex-dependent
ternary complex formation induces degradation of all
three proteins.
To determine whether the E3 ligase activity of Hdm2
is responsible for GR ubiquitylation and degradation,
HCT116 p53−/− cells were transfected with GR, p53, and
the Mdm2mutants R and C462A, which abolish the E3
ligase activity of Mdm2 (Argentini et al. 2000). Mdm2
promoted the degradation of both p53 and GR, whereas
the mutants protected both proteins from degradation
Figure 5. Dexamethasone induces cytoplasmic colocalization of p53, GR, and Hdm2 under hypoxia. (A–E) HUVEC were grown with
vehicle (no ligand) or 10−7 M Dex for 18 h in normoxia (A) or hypoxia (B–E), without (A,B) or with (C–E) 50 µM LLnL. Fixed cells were
incubated with antibodies against (A–C) GR (E-20 and P-200) and p53 (DO-1); (D) GR (E-20 and P-20) and Hdm2 (2A10); (E) p53 (588)
and Hdm2 (2A10), secondary antibodies, and analyzed by confocal microscopy. (F) Quantitation of panels (C–E). The cells were grown
without (a,c,e) or with (b,d,f) 10−7 M Dex. At least 500 cells were counted for each graph. The percentage of cells with protein in the
nucleus (N), cytoplasm (C), and both (N + C) are shown. (a,b) p53 + GR; (c,d) Hdm2 + GR; (e,f) Hdm2 + p53.
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(Fig. 6F). These results show that Mdm2 E3 ligase activ-
ity is required for GR degradation.
Dex-dependent ternary complexes involving p53, GR,
and Hdm2 form during mitomycin C treatment
To determine whether DNA damage could stimulate
Dex-dependent degradation of GR, we treated HUVEC
cells with mitomycin C (Fritsche et al. 1993). Similar to
hypoxia, mitomycin C stabilized p53 and GR in HUVEC
cells (Fig. 7A, lanes 1,3). Dex reduced induction of both
GR and p53 (Fig. 7A, lanes 2,3), and inhibited a down-
stream function of p53, apoptosis (data not shown). In-
hibition of proteasome-mediated degradation with LLnL
stabilized both proteins (Fig. 7A, lanes 4,5). These results
Figure 6. Dex stimulates the formation of a trimeric
complex between p53, GR, and Hdm2 and ubiquityla-
tion of GR and p53 by the E3 ligase activity of Hdm2.
(A) HUVEC were grown in the presence of 50 µM
LLnL and vehicle (−, ethanol) or 10−7 M Dex for 18 h
under hypoxic conditions. Lysates (500 µg) were im-
munoprecipitated with antibodies against p53 (421) or
GR (E-20 and P-20). Immunoprecipitates (IP) were
Western blotted with antibodies against GR and
Hdm2 (for p53 IP; a,b) or Hdm2 and p53 (for GR IP;
d,e). The efficiency of IP was verified with self-anti-
bodies (c,f). DO-1 was used to reveal p53 on the West-
ern blots. (Lanes 1,3,5,7) +Dex; (lanes 2,4,6,8) (−, ve-
hicle). Input, 10% lysate used for IP. (B) HepG2 cells
were grown in the presence of 50 µM LLnL and ve-
hicle (−, ethanol) or 10−7 M Dex for 12 h. Lysates (500
µg) were immunoprecipitated with antibodies against
GR (E-20 and P-20). The IPs were Western blotted
with antibodies against Hdm2 and p53 (a,b). The ef-
ficiency of IP was checked with self-antibodies (c).
(Lanes 1,3) +Dex; (lanes 2,4) (−, vehicle). Input, 10%
lysate used for IP. (C) HUVEC cells were transfected
(lanes 1–4) with HA-Ub, pBC–IP3.2, or pBC, and 24 h
posttransfection subjected to hypoxia for 18 h with
LLnL (50 µM) and either vehicle (−, ethanol) or 10−7 M
Dex. Lysates (500 µg) were immunoprecipitated with
antibodies against HA (12CA5). The IPs were Western
blotted with antibodies against with GR (E-20 and
p-20) (a) and p53 (DO-1) (b). (D) HCT116 p53 (WT)
(lanes 1,2,5,6) or HCT116 p53−/− (lanes 3,4,7,8) cells
were transfected with pHA–Ub, pBC–IP3 (where indi-
cated), and pEGGFP-C1 (lanes 5–8, to measure trans-
fection efficiency). Twelve hours posttransfection the
cells were incubated with 10−7 M Dex under hypoxia
for 12 h, with (lanes 1–4) or without (lanes 5–8) 50 µM
LLnL. Lysates (500 µg) from cells grown in the pres-
ence of LLnL were immunoprecipitated with antibod-
ies against HA (12CA5). The IPs were Western blotted
with antibodies against GR (E-20 and p-20; a). Lysates
(50 µg) from cells with LLnL were Western blotted
with antibodies to (b) GR (E-20 and P-20); (c) p53 (DO-
1); (d) GFP (monoclonal). (Lanes 1,3,5,7) −IP3; (lanes
2,4,6,8) +IP3. (E) HCT116 p53−/− cells were transfected
with pcDNA3–GR, pRC p53 (WT) pRC p53(22,23),
pxMDM2, and pEGGFP-C1 (to measure transfection
efficiency). Twelve hours posttransfection the cells
were subjected to hypoxia for 12 h with 10−7 M Dex.
Lysates (50 µg) were Western blotted with antibodies
against (a) GR (E-20 and P-20); (b) p53 (1801); c) Hdm2
(2A10); (d) GFP (monoclonal). (Lane 1) Mock transfec-
tion; (lane 2) GR; (lane 3) p53 + GR; (lane 4)
p53 + GR + Hdm2; (lane 5) p53(22,23) + GR + Hdm2.
(F) HCT116 p53−/− cells were transfected with
pcDNA3–GR, pRC p53 (WT), pxMDM2, px R, and
pxC462A. Twelve hours posttransfection the cells were subjected to hypoxia for 12 h with 10−7 M Dex. Lysates (50 µg) were Western
blotted with antibodies against (a) Hdm2 (2A10); (b) GR (E-20 and P-20); (c) p53 (DO-1); (d) TBP (3G3). (Lane 1) Mock transfection; (lane
2) p53 + GR; (lane 3) p53 + GR + R; (lane 4) p53 + GR + Hdm2; (lane 5) p53 + GR + C462A.
Sengupta and Wasylyk
2374 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on August 30, 2017 - Published by genesdev.cshlp.orgDownloaded from 
show that both p53 and GR undergo enhanced degrada-
tion in the presence of Dex during mitomycin C treat-
ment.
We determined whether the cellular localization of
p53 and GR are the same in mitomycin C as in hypoxia-
treated cells. HUVEC cells were treated with mitomycin
C in the presence of LLnL, and the cells examined by
indirect immunofluorecence. Typical cells are shown in
Figure 7. Dexamethasone induces degradation, cytoplasmic accumulation, and trimeric complex formation of p53, GR, and Hdm2
following mitomycin C treatment. (A) HUVEC cells were grown for 24 h with vehicle (ethanol), 10−7 M Dex, and 50 µM LLnL, as
indicated, and with (lane 1) or without (lanes 2–5) 10 µM mitomycin C. Lysates (50 µg) were Western blotted with antibodies against
(a) p53 (DO-1); (b) GR (E-20 and P-20); (c) TBP (3G3). (Lanes 1,3,5) (−,vehicle); (lanes 2,4) +Dex. (B–D) HUVEC were grown with 10 µM
mitomycin C, 50 µM LLnL, vehicle (no ligand), or 10−7 M Dex for 24 h. The cells were fixed, incubated with antibodies [(B) GR (E-20
and P-20) and p53 (DO-1); (C) GR (E-20 and P-20) and Hdm2 (2A10); (D) p53 (588) and Hdm2 (2A10)], secondary antibodies, and analyzed
by confocal microscopy. (E) Quantitation of (B–D). The cells were grown without (a,c,e) or with (b,d,f) 10−7 M Dex. At least 500 cells
were counted for each graph. The percentage of cells with protein in the nucleus (N), cytoplasm (C), and both (N + C) are shown. (a,b)
p53 + GR; (c,d) Hdm2 + GR; (e,f) Hdm2 + p53. (F) HUVEC were incubated with 50 µM LLnL, vehicle (−, ethanol) or 10−7 M Dex, and
10 µM mitomycin C for 24 h. Lysates (500 µg) were immunoprecipitated with antibodies against GR (E-20 and P-20). The IPs were
Western blotted with antibodies against Hdm2 and p53 (a,b). The efficiency of IP was verified with self-antibodies (c). (Lanes 1,3) +Dex;
(lanes 2,4) (−, vehicle). Input, 10% lysate used for IP.
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Figure 7B–D and the quantitation in Figure 7E. In the
absence of Dex, mitomycin C treatment resulted in
nuclear accumulation of p53, whereas GR remained cy-
toplasmic. However, in the presence of Dex, p53 as well
as GR were cytoplasmic and colocalized extensively (Fig.
7B). Similar Dex-dependent colocalization was observed
when cells were examined for GR and Hdm2 (Fig. 7C) or
for p53 and Hdm2 (Fig. 7D). These results show that p53,
GR, and Hdm2 are colocalized in the presence of Dex
during mitomycin C treatment, and suggest that they
could form a triple complex. Indeed, GR antibody immu-
noprecipitates from mitomycin C-treated HUVEC cells
grown in the presence of LLnL were found to contain
both Hdm2 and p53, to a much larger extent in the
presence than in the absence of Dex (Fig. 7F, cf. lanes 3
and 4).
Discussion
Glucocorticoids and their receptors play important roles
in both apoptotic cell death and cellular proliferation. An
agonist of the glucocorticoid receptor, Dex, is known to
induce apoptosis in T cells, B lymphocytes, and multiple
myoloma cells (Martin and Green 1995). However, it
also represses apoptosis and increases proliferation in
cancer cell lines (Chang et al. 1997), neutrophils (Daffern
et al. 1999), retinal pigment cells (He et al. 1994), fibro-
blasts (Li et al. 1998), rat hepatoma (Yamamoto et al.
1998), and serum-depleted T lymphocytes that express
Bcl2 (Huang and Cidlowski 1999). The divergent func-
tions of glucocorticoids and GR in different contexts can
be attributed to interactions with different pro- and an-
tiproliferation factors. For example, GR interacts with
and affects the functions of the proapoptotic protein
DAP3 (Hulkko et al. 2000). Here we show that GR and
the tumor supressor p53 regulate, by novel mechanisms,
each other’s functions in normal cells in response to a
physiological stress.
We have demonstrated that Dex induces mutual
down-regulation of p53 and GR-dependent downstream
target genes, both under hypoxia in HUVEC and under
normoxia in HepG2 cells. HUVEC are normal human
cells with typical GR-dependent functions. Under nor-
moxic conditions, in which p53 levels are very low, HU-
VEC display a ligand-dependent translocation of the re-
ceptor to the nucleus and transactivation of GR down-
stream genes such as PEPCK and G-6-Pase. However,
under hypoxia, which induces a large increase in p53
levels, GR functions are seriously impaired. p53 induc-
tion may not be required in HepG2 because its levels are
constitutively high. Down-regulation of GR, which oc-
curs within 3 h in HepG2, takes about 12–18 h in HU-
VEC, probably due to the time required to increase p53
levels. The constitutively high level of p53 in HepG2
could account for the reported insensitivity of HepG2 to
Dex induction of GR activity (Xing and Quinn 1993).
We have shown, in vitro and in vivo, that GR and p53
interact weakly in the absence of ligand and more
strongly in the presence of Dex. Interestingly, GR inter-
acts with the NLS of p53, and apparently only in the
presence of ligand. This interaction could result in li-
gand-dependent masking of the NLS, sequestration in
the cytoplasm, and in consequence, inhibition of trans-
activation. However, we cannot exclude that the com-
plex accelerates nuclear export of both proteins.
We have found that GR and p53 inhibit each other’s
activities by cytoplasmic sequestration in response to
hypoxia and DNA damage in a ligand-dependent man-
ner. Hypoxia and DNA damage can be expected to have
similar effects. Hypoxia is a potent inducer of Nitric Ox-
ide Synthase in rats and endothelial cells of bovine origin
(Arnet et al. 1996; Gess et al. 1997). Nitric oxide oxy-
radicals damage DNA (Xu et al. 2000), and up-regulate
p53 (Forrester et al. 1996). We have previously shown
that neuroblastoma cells represent a pathological situa-
tion in which p53 is inhibited by cytoplasmic sequestra-
tion (Sengupta et al. 2000b). There is growing evidence
that p53 sequestration in the cytoplasm may be a com-
mon mechanism of p53 inactivation. For example, both
Mot-2 (Wadhwa et al. 1999) and hepatitis B virus X pro-
tein (Elmore et al. 1997) have been shown to physically
interact with p53 and repress its transcriptional activity
by sequestration in the cytoplasm. Estradiol inactivates
p53 by intracellular redistribution (Molinari et al. 2000).
The results from experiments with in vitro translated
proteins and overexpression in cells suggest that p53
down-regulates ER-responsive genes by interfering with
the binding of ER to ERE (Liu et al. 1999). Moreover, ER
protects p53 from Hdm2-mediated degradation through
the formation of a triple complex (Liu et al. 2000). Cy-
toplasmic sequestration and functional repression of p53
in mammary epithelium can be reversed with a hormone
cocktail (Kuperwasser et al. 2000). However, in none of
these studies was the subcellular localization of the
complex and the relevance of the interactions to physi-
ological conditions addressed.
We have established that Dex stimulates the forma-
tion of a triple complex that contains Hdm2 in addition
to p53 and GR. This triple complex apparently forms by
GR and Hdm2 binding to different domains of p53.
Hdm2 binds to the N-terminal transactivation domain,
whereas GR binds to the DNA binding domain and the
NLS. Interestingly, Hdm2 recruitment is associated with
increased ubiquitylation and proteasome-mediated deg-
radation of p53 and GR. In contrast, ER apparently in-
hibits Hdm2-mediated degradation of p53 (Liu et al.
2000). Dex induces cytoplasmic accumulation of Hdm2,
triple complex formation, and degradation, suggesting
that degradation is mediated by cytoplasmic protea-
somes. Hdm2-mediated degradation of p53 is generally
thought to occur in the cytoplasm. However, a recent
study suggests that it may also occur in the nucleus (Yu
et al. 2000). In neuroblastoma cells both p53–Hdm2
(Zaika et al. 1999) and p53–GR (Sengupta et al. 2000b)
complexes are found in the cytoplasm, suggesting that
the cytoplasmic degradation function of Hdm2 is defec-
tive in these cells. Thus, lack of degradation as well as
cytoplasmic sequestration distinguish neuroblastoma
from normal cells.
We have discovered that GR is a new substrate for
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Hdm2, thereby extending the range of targets for this E3
ubiquitin ligase. Mdm2 mediates degradation of the cell
fate regulator Numb (Juven-Gershon et al. 1998) and E2F
(Loughran and La Thangue 2000) in a p53-independent
manner. In contrast, it targets GR (this study) and HIF-1
(Ravi et al. 2000) in a p53-dependent manner. It is con-
ceivable, therefore, that p53-mediated recruitment of
Mdm2 is an important mechanism for the degradation of
proteins that interact with p53 under different physi-
ological conditions.
It is interesting to consider why p53 and GR cross talk
under physiological conditions. Both p53 and GR medi-
ate stress responses, but with intrinsic differences in
their actions. GR, when complexed to glucocorticoids, is
involved in fight-or-flight responses, and maintains ho-
meostasis during internal or environmental changes.
Hence, GR is generally involved in a survival response.
On the other hand, p53, which has been described as the
“guardian of the genome,” responds to extensive geno-
mic and other stresses by inducing cell death. p53 can be
considered to be a death response. Hence, p53 and GR
can be considered to be protagonists in the question of
life or death, and should, therefore, have antagonistic
effects on each other’s functions. Hypoxia and the sub-
sequent DNA damage represent such a situation where
p53 and GR have opposite effects. The death response via
p53 is held in check by ligand-activated GR, which in-
duces p53 degradation. GR itself is also restrained by
increased degradation induced by p53. Mutual negative
cross talk between these factors thereby functions as a
balance between the cellular responses to conflicting sig-
nals.
In summary, we have demonstrated for the first time
that p53 and GR functionally cross talk under physi-
ological conditions. We have also identified p53 and GR
downstream genes that are down-regulated during this
process. The repression of each other’s functions is en-
hanced by ligand. The core domain and NLS of p53 bind
to GR in a ligand-enhanced manner, resulting in the cy-
toplasmic relocalization of both proteins. The p53–GR
complex in the cytoplasm also contains the E3 ubiquitin
ligase Hdm2, which mediates degradation of both p53
and GR. Although GR degradation by the ubiquitin pro-
teasome machinery has been postulated, our studies pro-
vide the first direct evidence for it in a physiological
situation.
Material and methods
Recombinants
GST constructs GST–p53(305–321) was generated by ligating
oligonucleotides into the BamHI and EcoRi sites of pGEX-2T
(Pharmacia Biotech). The other p53 mutants were generated by
PCR and cloning into the same sites of pGEX-2T.
Reporters, expression vectors, and cDNA probes p53CON
(Funk et al. 1992); CTS1 (Conseiller et al. 1998); pcDNA3GR
(Sengupta et al. 2000b); CMV–LacZ, IGBMC core facility; pBC–
IP3.2 (Wasylyk et al. 1999); HA-Ub (Treier et al. 1994); pBS–-
actin (IGBMC core facility); pBS–glucose-6-phosphate (Lange et
al. 1994); pBS–PEPCK (Bartels et al. 1989); pRCp53(WT) and
pRCp53(22,23) (Lin et al. 1994); pxMDM2, pxR, pxC462A (Ar-
gentini et al. 2000); pEGGFP-C1 (Clonetech).
Cells
HSC-2 (Momose et al. 1989); HUVEC, ATCC (CRL-1730);
HepG2, ECACC (Ref. 85011430); HCT116 p53(WT) and
HCT116 p53(−/−) (Bunz et al. 1998).
Protein expression, purification, and GST interactions
GST proteins were induced with 1 mM IPTG in E. coli DH5
grown at 25°C, and extracted by sonication in STE buffer (10
mM Tris-HCl at pH 8.0; 150 mM NaCl; 1 mM EDTA supple-
mented with 5 mM DTT, 1mM PMSF, 2.5 µg/mL proteinase
inhibitors and 1.5% Sarkosyl). The sonicate was adjusted to 2%
Triton X-100, agitated for 30 min at 4°C, centrifuged, and the
crude extract stored in aliquots at −70°C. Glutathione-S-Seph-
arose beads were equilibrated in GST buffer (50 mMTris-HCl at
pH 7.5, 100 mM KCl, 10 mM MgCl2, 5% glycerol, 0.5% NP-40
supplemented with 0.3 mM DTT, 1 mM PMSF and 2.5 µg/mL
proteinase inhibitors), incubated with the crude extracts at 4°C
for 90 min, and washed. Bound proteins were analyzed by SDS-
PAGE and Coomassie staining. GR was produced by in vitro
translation with pcDNA3GR and the TNT Quick coupled tran-
scription/translation system (Promega) for 90 min at 30°C.
Equivalent amounts of bound protein were incubated with 5 µL
of in vitro translated GR for 1 h at 4°C in the presence of vehicle
(ethanol), Dex, Cortisol, or RU486 (Sigma). The bound proteins
were washed and analyzed by SDS-PAGE and fluorography.
Cell culture and transfection
Cells were maintained in DMEM plus 10% serum and antibi-
otics at 37°C with 5% CO2. HUVEC medium was supple-
mented with ECGF (50 µg/mL), Heparin (50 µg/mL), and Glu-
tamine (1 mM). The HCT116 cell lines were grown in McKoy’s
5A medium plus 10% serum, antibiotics, and 2 mM glutamine.
HSC-2 were transfected by calcium phosphate precipitation
(Chen and Okayama 1987) with 4 µg of plasmid in 36-mm plates
(six-well cluster, Costar 3516). After 16 h the cells were washed
with medium and incubated in full medium with ligands or
vehicle (ethanol). To express HA-Ub and IP3, low-passage HU-
VEC (<15) was transfected with Superfect (QIAGEN) according
to the manufacturer’s instructions. After 3 h with Superfect the
cells were incubated in normal medium for 24 h. HCT116 cells
were transfected with Lipfectamine 2000 (Life Technologies) in
the presence of serum for 6 h, washed, and incubated in normal
medium for 12 h before hypoxic treatment. Post-transfection is
defined as after the removal of the facilitator. Hypoxia experi-
ments were carried out in anaerobic chambers (Anaerocult,
Merck, Cat. no. 1.13829) at 37°C according to the manufactur-
er’s instructions; 10 µM mitomycin C (Sigma) was used.
Transcriptional activity
Cell lysates were analyzed for luciferase and -galactosidase
activities as described previously (Sengupta et al. 2000a).
Western blots
Equal quantities of protein, estimated by the Bio-Rad assay on
RIPA buffer lysates, were fractionated by SDS-PAGE, trans-
ferred to nitrocellulose membranes (Schleicher and Schuell),
and Western blotted. Primary and secondary antibodies: Bax,
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N20 (Santa Cruz Biotechnology); p21WAF1/CIP1, 1WA-IC581
(Sengupta et al. 2000a); TBP, 3G3 (Brou et al. 1993); p53, DO-1
(Vojtesek et al. 1992); p53, PAb 421 (Wade-Evans and Jenkins
1985); p53, #588, raised against a GST–human p53(320–393) (C.
Wasylyk and the IGBMC core facility); GR, E-20 and P-20 (Santa
Cruz Biotechnology); PARP (Kaufmann et al. 1993); HA, 12CA5
(Boerhinger); PEPCK (Zimmer and Magnuson 1990); Hdm2,
2A10 (Chen et al. 1993); HIF-1, C-19 (Santa Cruz Biotechnol-
ogy); peroxidase-coupled anti-rabbit or anti-mouse antibodies
(Jackson Laboratories); p53, 1801 (Ab-2) (Oncogene Research
Products); GFP (Clontech). The blots were revealed by chemi-
luminescence (Pierce Super Signal).
Northern blots
Forty micrograms of total RNA, extracted with Trizol (GIBCO
BRL), was electrophoresed on 6% formaldehyde–1% agarose
gels, transferred to Hybond N+ membranes, hybridized with
random-primed probes at 55°C (for PEPCK and G-6-Pase) or
65°C (for p53, GR, and actin), washed, and autoradiographed.
Immunofluorescence
Cells were fixed with acetone:methanol (1:1), blocked with 10%
goat serum, incubated with primary antibodies for 2 h, second-
ary antibodies linked to either Cy3 or FITC (Moll et al. 1996)
and Hoechst (to stain nuclei), then visualized by confocal mi-
croscopy (Leica TCS 4D).
Immunoprecipitations
Cells were lysed on ice in NP-40 buffer (150 mM NaCl, 1%
NP-40, 50 mM Tris-HCl at pH 8.0) and the cleared supernatants
used for immunoprecipitation. The antigen–antibody complex
was allowed to form on ice for 1 h, then immobilized on protein
G beads, washed three times, boiled in Laemmli buffer, and
fractionated by SDS-PAGE.
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